en · de · es · fr · pt
aod-9604-notes.peptides3626.com › Wiki › Identity And Research Background — Deep Dive

Identity And Research Background — Deep Dive

By Editorial Desk · published 2025-12-11 · last reviewed 2025-12-27 · Wiki

If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideFragment analog of human growth hormone
Sequence basishGH 176–191 regionModified C-terminal fragment
Common synonymsAOD-9604; AOD9604; hGH fragmentResearch and trade names vary
Regulatory statusNot approved as a drugProhibited in competitive sport
Research codeAOD9604Used in scientific and patent literature

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Related pages on this site

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Notes from published material

== History == Citalopram was first synthesized in 1972 by chemist Klaus Bøgesø and his research group at the pharmaceutical company Lundbeck and was first marketed in 1989 in Denmark. It was first marketed in the US in 1998. The original patent expired in 2003, allowing other companies to legally produce and market generic versions.

Tourism in Brazil is a growing sector and key to the economies of several regions of the country. The country had 6.36 million visitors in 2015, ranking in terms of the international tourist arrivals as the main destination in South America and second in Latin America after Mexico. Revenues from international tourists reached US$6 billion in 2010, showing a recovery from the 2008–2009 economic crisis. Historical records of 5.4 million visitors and US$6.8 billion in receipts were reached in 2011. In the list of world tourist destinations, in 2018, Brazil was the 48th most visited country, with 6.6 million tourists (and revenues of 5.9 billion dollars). Natural areas are its most popular tourism product, a combination of ecotourism with leisure and recreation, mainly sun and beach, and adventure travel, as well as cultural tourism. Among the most popular destinations are the Amazon Rainforest, beaches and dunes in the Northeast Region, the Pantanal in the Center-West Region, beaches at Rio de Janeiro and Santa Catarina, cultural tourism in Minas Gerais and business trips to São Paulo. In terms of the 2024 Travel and Tourism Competitiveness Index (TTCI), which is a measurement of the factors that make it attractive to develop business in the travel and tourism industry of individual countries, Brazil ranked in the 26th place at the world's level, third in the Americas, after Canada and United States. Domestic tourism is a key market segment for the tourism industry in Brazil.

Double-blind trials have shown no difference in behavior between children given sugar-full or sugar-free diets, even in studies specifically looking at children with attention deficit hyperactivity disorder or those considered sensitive to sugar. A 2019 meta-analysis found no positive effect of sugar consumption on mood but did find an association with lower alertness and increased fatigue within an hour of consumption, known as a sugar crash. Sugar can, however, lead to a jump in blood sugar levels, and may make a child more active even if it does not cause clinical hyperactivity. Eating nuts, popcorn, or seeds does not increase the risk of diverticulitis. These foods may actually have a protective effect. Eating less than an hour before swimming does not significantly increase the risk of experiencing muscle cramps, and does not increase the risk of drowning. One study shows a correlation between alcohol consumption and drowning, but not between eating and stomach cramps. Vegan and vegetarian diets can provide enough protein for adequate nutrition. In fact, typical protein intakes of ovo-lacto vegetarians meet or exceed requirements. The American Dietetic Association maintains that appropriately planned vegetarian diets are healthful. However, a vegan diet does require dietary supplements. Swallowed chewing gum does not take seven years to digest. Chewing gum is mostly indigestible, and passes through the digestive system at the same rate as other matter.

=== Stroma === The stroma of the bone marrow includes all tissue not directly involved in its primary function of hematopoiesis. Stromal cells support hematopoiesis indirectly by providing a specialized microenvironment that influences the function and differentiation of hematopoietic cells. For example, they produce colony-stimulating factors, which play a significant role in regulating blood cell formation. Cell types that constitute the bone marrow stroma include:

Sources: en.wikipedia.org

Further detail

The Cuban activist and historian Emilio Roig de Leuchsenring wrote of Freemasonry in Cuba:"To fully express what Freemasonry represents for us in a few words, suffice to say that, without mentioning it once, twice and perhaps a thousand times, one cannot write the history of Cuban culture or Cuba's struggle for freedom."

=== Ischemia and hypoxia === Blood vessels constrict in tissue that becomes cold and dilate in warm tissue, altering blood flow to the area. Thus keeping the tissues warm is probably necessary to fight both infection and ischemia. Some healthcare professionals use 'radiant bandages' to keep the area warm, and care must be taken during surgery to prevent hypothermia, which increases rates of post-surgical infection. Underlying ischemia may also be treated surgically by arterial revascularization, for example in diabetic ulcers, and patients with venous ulcers may undergo surgery to correct vein dysfunction. Diabetics that are not candidates for surgery (and others) may also have their tissue oxygenation increased by Hyperbaric Oxygen Therapy, or HBOT, which may provide a short-term improvement in healing by improving the oxygenated blood supply to the wound. In addition to killing bacteria, higher oxygen content in tissues speeds growth factor production, fibroblast growth, and angiogenesis. However, increased oxygen levels also means increased production of ROS. Antioxidants, molecules that can lose an electron to free radicals without themselves becoming radicals, can lower levels of oxidants in the body and have been used with some success in wound healing. Low level laser therapy has been repeatedly shown to significantly reduce the size and severity of diabetic ulcers as well as other pressure ulcers. Pressure wounds are often the result of local ischemia from the increased pressure.

== Applications == Because of the ability of acetalated dextran to degrade more rapidly in low pH environments like the phagolysosome of a macrophage or dendritic cell, it has been used as polymeric micro/nanoparticles. Acetalated dextran was originally developed as a vaccine carrier, but has been used for drug delivery, tissue engineering and infectious disease vaccine delivery. Its unique degradation rates have led to finely tuned release of therapeutic proteins and vaccine elements. Ac-DEX has also been shown the allow proteins to be stored outside the cold chain. Formation of nanoparticles with Ac-DEX can be made through standard methods like emulsion, spray drying and electrospray. Using sonication, inorganic nanoparticles have been embedded into Ac-DEX particles to for a composite material for cancer therapy."Prickly Nanoparticles against Cancer". article. Weinheim, Germany. 2017-03-09. Retrieved 2024-09-16. Also they have been used as a core material for cell membrane coating.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.

Was AOD-9604 approved for weight loss?

It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.

Why is AOD-9604 banned in sports?

WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network